HOME >> MEDICINE >> NEWS
Trial shows malaria vaccine could protect young children from disease for 18 months

The RTS, S/AS02A vaccine could protect young African children against a range of clinical disease caused by the malaria parasite for at least 18 months, concludes a randomised trial published online today (Tuesday November 15, 2005) by The Lancet.

Early trials of the RTS, S/AS02A vaccine have shown that the vaccine is safe, well tolerated, and can trigger an immune response. In one of the trials, involving over 2000 Mozambican children aged 1-4 years, Pedro Alonso (University of Barcelona, Spain) and colleagues found that after 6 months' follow-up the vaccine reduced the risk of clinical malaria by 30%, delayed time to first infection by 45%, and reduced the risk of severe malaria by 58%. In the latest study the investigators followed-up the children for a further 12 months. They found that the efficacy of the drug did not wane and that protection against clinical malaria lasted for at least 18 months after vaccination. The study shows that the vaccine reduces the risk of clinical malaria by 35% and nearly halves the risk of severe malaria over a period of 18 months.

Professor Alonso states: "Our results show that the RTS,S/AS02A candidate malaria vaccine confers partial protection for at least 18 months against a range of clinical diseases caused by P falciparum in children living in a rural malaria endemic area of African The combination of sustained protection together with substantial prevention of the severe forms of malaria marks RTS, S/AS02A as a promising vaccine candidate and strongly suggests that malaria vaccines have an important role as future public-health instruments."

The publication coincides with a presentation at the Fourth Multilateral Initiative on Malaria Pan-African Malaria Conference 2005 in Yaounde, Cameroon.


'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
15-Nov-2005


Page: 1

Related medicine news :

1. Trial stops after stroke and mortality significantly reduced by blood
2. Trials underway for essential new TB vaccine
3. Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy
4. ENDEAVOR III Trial reports key findings on new-generation stent
5. NIH names Clinical Trial Units for the Microbicide Trials Network
6. Clinical Trials Units selected for newly restructured HIV/AIDS research networks
7. The Public Library of Science launches the new open access journal PLoS Clinical Trials
8. Trial shows vaccine against cervical cancer provides long-term protection
9. Trial demonstrates new drugs effectiveness against psoriasis
10. Trial at Jefferson shows new drug may help cancer patients who need stem cell transplants
11. Second implant of US Pilot Trial achieved

Post Your Comments:
(Date:10/25/2014)... CA (PRWEB) October 25, 2014 ... biology, today announced Dr. Xun Wang ... all Research & Development. , Triton has developed a ... value algae-based proteins. According to Dr. Wang, the platform ... traditional expression systems. He says, “Algae are unique because ...
(Date:10/25/2014)... (PRWEB) October 25, 2014 The global ... CAGR of 7.6%, to reach $50.4 billion by 2018 ... healthcare systems industry, and pharmaceutical industry are driving the ... model to enhance their focus on core business, reduce ... and trained staff (further reducing hiring and training costs), ...
(Date:10/25/2014)... Background: , In 1998 Bob Savage founded the Connecticut ... the field of establishing recovery community organizations. Bob had ... he retired, he set out to answer a couple questions ... , 1. Where are the people in recovery when ... Can the recovery community be organized to advocate for issues ...
(Date:10/25/2014)... 2014 Market Research Report ... 2009-2019 is a professional and in-depth market ... industry. The report firstly reviews the basic ... application and manufacturing technology. The report then ... Molecular Diagnostics listing their product specification, capacity, ...
(Date:10/25/2014)... York (PRWEB) October 25, 2014 ... lawsuits ( http://www.vaginalmeshlawsuit2015.com/ ) filed against Boston ... in U.S. District Court, Southern District of West ... Judgment on Punitive Damages in a group of ... a ruling issued on October 21st, U.S. District ...
Breaking Medicine News(10 mins):Health News:Triton Algae Innovations Ltd. Names Dr. Xun Wang as President 2Health News:Triton Algae Innovations Ltd. Names Dr. Xun Wang as President 3Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 2Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 3Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 4Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4
(Date:10/25/2014)...  In 2008, two of Dr. Gurney,s employees reported ... substances, on a regular basis, that were not used ... was practicing "all the time" while under the influence. ... said that Dr. Gurney was prone to "making mistakes ... Dr. Gurney,s behavior became increasingly erratic and unfocused, and ...
(Date:10/25/2014)... , Oct. 24, 2014 In conjunction ... quarter 2014 financial results press release, you are invited ... broadcast live over the internet on Monday, November 3, ... Time). A live audio webcast of the ... http://www.durect.com and clicking "Investor Relations."  If you ...
(Date:10/25/2014)... , Oct. 24, 2014 Burzynski Research Institute, ... Drug Administration (FDA) has given the company permission to ... in patients > 3 months of age with a ... placed in one of five treatment groups based on ... prior treatment for DIPG. The primary study endpoint is ...
Breaking Medicine Technology:Doctors That Harm: The Real Stories Insurance Companies Against Prop 46 Don't Want You To Know, Part 8 of Consumer Watchdog Campaign Series 2Doctors That Harm: The Real Stories Insurance Companies Against Prop 46 Don't Want You To Know, Part 8 of Consumer Watchdog Campaign Series 3DURECT Corporation Invites You to Join its Third Quarter 2014 Earnings Conference Call 2Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2
Cached News: